AVBP - ArriVent BioPharma, Inc. Common Stock
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$44.00
DETAILS
HIGH:
$45.00
LOW:
$43.00
MEDIAN:
$44.00
CONSENSUS:
$44.00
UPSIDE:
64.61%
About ArriVent BioPharma, Inc. Common Stock (https://www.arrivent.com)
ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. It also engages in the development and commercialization of targeted cancer therapies for non-small-cell lung cancer (NSCLC) and other solid tumors. The company develops Furmonertinib, an epidermal growth factor receptor mutant-selective tyrosine kinase inhibitor that is in phase 3 clinical trial for the treatment of NSCLC patients; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Zhengbin Yao | Co-Founder, Chairman, President & Chief Executive Officer | 1966 | $968,667 USD |
| Stuart Lutzker | Co-Founder, President of Research & Development and Director | 1961 | $777,353 USD |
| Winston Kung | Chief Financial Officer & Treasurer | 1976 | $752,704 USD |
| Robin LaChapelle | Co-Founder & Chief Operating Officer | 1973 | $586,453 USD |
| Brent S. Rice | Chief Commercial Officer | 1966 | – |
| James Paul Kastenmayer | General Counsel & Secretary | 1972 | – |
| Yang Wang | Chief Technology Officer | – | – |